Clinical Trials
Below are current clinical trials.
265 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.
-
Rochester, Minn.
The purpose of this study is to investigate the effectiveness and safety of Rivaroxaban for reducing the risk of major venous and arterial thrombotic events, hospitalization and death in medically ill outpatients with acute, symptomatic COVID-19 infection.
-
Rochester, Minn.
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated. Each subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.
-
Rochester, Minn.
The purpose of this study is to determine the safety and tolerability of ixazomib in HIV infected patients who are on a stable regimen of ART that suppresses HIV replication, and to determine the effectiveness of ixazomib on reservoir T cells that are infected with HIV DNA.
-
Rochester, Minn.
The purpose of this study is to determine if Clofazimine is effective in treating patients with drug resistant non-tuberculous mycobacterial infections.
-
Rochester, Minn.
The purpose of this randomized, double-blind, placebo-controlled trial of intravenous hyperimmune immunoglobulin (Flu-IVIG) in individuals with influenza A or B is to determine the pharmacokinetic (PK) profile of Flu-IVIG and assess whether antibody levels observed following Flu-IVIG transfusion are similar to those predicted. This pilot study will inform a larger study that will be powered to compare Flu-IVIG with placebo for efficacy.
-
Rochester, Minn.
The purposes of this study are to determine if patients treated with fluoroquinolone (FQ) antibiotics have depletion of mitochondrial DNA (mtDNA) in buccal swab samples, and whether the degree of depletion correlates with the likelihood of developing FQ-associated toxicity.
2nd arm - An additional group of patients will be enrolled if they previously received FQ antibiotics. appear to be symptomatic and have a previously collected muscle or nerve biopsy for clinical purposes available for this research study.
-
Rochester, Minn.
The purpose of this study is to develop a colorimetric test for influenza virus detection in a chemically engineered cup/tube. When sample fluid (saliva) is in the tube, the fluid color turning blue indicates a positive result. We are in the process of developing this test, and will test on saliva samples from flu patients.
-
Rochester, Minn.
The purpose of this study is to characterize mucosal and luminal microbiome in patients diagnosed with Clostridium difficile infection (CDI), at the time of diagnosis and after treatment, to determine the effect of mucosa associated microbiome on outcome of CDI and the effect of antibiotic treatment on mucosa associated microbiome
-
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The purpose of this study is compare high dose (69.6 mg/day) Zinc to multivitamin supplementation on immune health as used by primary health care staff and individuals over 50 years old identified, by hypothesis generated from observations among the pandemic to date, as being at risk populations to COVID-19. In order to ensure consistent nutritional supplementation, the PreserVision AREDS formulation gel tabs will be recommended for those randomized to Zinc and the Adult (under 50) Centrum formulation recommended for those randomized to multivitamin.